Gomaa Adel A, Abdel-Wadood Yasmin A
Department of Medical Pharmacology, Faculty of Medicine, Assiut Universitya, Beni-Suif, Egypt.
Assiut, Faculty of Agriculture, Beni-Suif University, Beni-Suif, Egypt.
Phytomed Plus. 2021 Aug;1(3):100043. doi: 10.1016/j.phyplu.2021.100043. Epub 2021 Feb 17.
Several recent studies have stated that glycyrrhizin and licorice extract are present in most traditional Chinese medicine formulas used against SARS-CoV-2 in China. Significant data are showing that glycyrrhizin and licorice extract have multiple beneficial activities in combating most features of SARS-CoV-2.
The aim of current review was to highlight recent progresses in research that showed the evidence of the potential use of glycyrrhizin and licorice extract against COVID-19.
We have reviewed the information published from 1979 to October 2020. These studies demonstrated the effects , use and safety of glycyrrhizin and icorice extract against viral infections,bacterial infections, inflammatory disorders of lung ( in vitro and in vivo). These studies were collated through online electronic databases research (Academic libraries as PubMed, Scopus, Web of Science and Egyptian Knowledge Bank).
Pooled effect size of articles provides information about the rationale for using glycyrrhizin and licorice extract to treat COVID-19. Fifty studies demonstrate antiviral activity of glycyrrhizin and licorice extract. The most frequent mechanism of the antiviral activity is due to disrupting viral uptake into the host cells and disrupting the interaction between receptor- binding domain (RBD) of SARS-COV2 and ACE2 in recent articles. Fifty studies indicate that glycyrrhizin and licorice extract have significant antioxidant, anti-inflammatory and immunomodulatory effects. Twenty five studies provide evidence for the protective effect of glycyrrhizin and licorice extract against inflammation-induced acute lung injury and cardiovascular disorders.
The current study showed several evidence regarding the beneficial effects of glycyrrhizin and licorice extract in combating COVID-19. More randomized clinical trials are needed to obtain a precise conclusion.
最近的几项研究表明,中国用于对抗新型冠状病毒肺炎(SARS-CoV-2)的大多数中药配方中都含有甘草酸和甘草提取物。大量数据显示,甘草酸和甘草提取物在对抗新型冠状病毒肺炎的大多数特征方面具有多种有益作用。
本综述的目的是强调最近的研究进展,这些进展显示了甘草酸和甘草提取物对抗新型冠状病毒肺炎(COVID-19)的潜在用途的证据。
我们回顾了1979年至2020年10月发表的信息。这些研究证明了甘草酸和甘草提取物在体外和体内对抗病毒感染、细菌感染、肺部炎症性疾病的作用、用途和安全性。这些研究是通过在线电子数据库研究(如PubMed、Scopus、Web of Science和埃及知识库等学术图书馆)整理的。
文章的综合效应量提供了使用甘草酸和甘草提取物治疗新型冠状病毒肺炎的理论依据。五十项研究证明了甘草酸和甘草提取物的抗病毒活性。在最近的文章中,抗病毒活性最常见的机制是破坏病毒进入宿主细胞以及破坏新型冠状病毒2(SARS-CoV-2)的受体结合域(RBD)与血管紧张素转换酶2(ACE2)之间的相互作用。五十项研究表明,甘草酸和甘草提取物具有显著的抗氧化、抗炎和免疫调节作用。二十五项研究为甘草酸和甘草提取物对炎症诱导的急性肺损伤和心血管疾病的保护作用提供了证据。
目前的研究显示了关于甘草酸和甘草提取物在对抗新型冠状病毒肺炎方面有益作用的若干证据。需要更多的随机临床试验来得出精确的结论。